Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The ...

The drugs “are exciting because they work,” Lucy says, but there “has not been much innovation” in linker chemistry. Lucy says Siftr could make a real impact by improving spatial and ...

今年8月，Adcendo以总计超10亿美元的里程碑付款从中国biotech普众发现引进一条核心ADC管线。短短3个月后，Adcendo宣布完成由TCGX领投，Novo ...

自研管线之中比较有特色的首推三抗：BG-T187，靶向EGFR和c-MET（c-MET为双表位）两个靶点，于今年获批九月获批临床。关于这两个靶点首先想到的应该是强生的同靶点埃万妥单抗，不过强生的是双抗，比较出色的战绩自然是《盲盒开出王炸：肺癌领域大变 ...

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a ...

Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...

Roche's Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. | Roche's Chugai Chugai ...

Adcentrx begins patient dosing in phase 1a/b study of ADRX-0405, a potential first-in-class ADC targeting STEAP1 to treat advanced solid tumours: San Diego, California Wednesday, ...

via a chemical linker. ADCs leverage the mAb's specificity for a tumor-associated antigen to achieve targeted cytotoxic drug delivery to tumor cells. Once an ADC binds to its target antigen on a t ...